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Abstract
Heparan and chondroitin sulfate proteoglycans (HSPGs and CSPGs, respectively) regulate
numerous cell surface signaling events, with typically opposite effects on cell function. CSPGs
inhibit nerve regeneration through receptor protein tyrosine phosphatase sigma (RPTPs). Here we
report that RPTPs acts bimodally in sensory neuron extension, mediating CSPG inhibition and
HSPG growth promotion. Crystallographic analyses of a shared HSPG-CSPG binding site reveal a
conformational plasticity that can accommodate diverse glycosaminoglycans with comparable
affinities. Heparan sulfate and analogs induced RPTPs ectodomain oligomerization in solution,
which was inhibited by chondroitin sulfate. RPTPs and HSPGs colocalize in puncta on sensory
neurons in culture, whereas CSPGs occupy the extracellular matrix. These results lead to a model
where proteoglycans can exert opposing effects on neuronal extension by competing to control the
oligomerization of a common receptor.
Type IIa receptor protein tyrosine phosphatases (RPTPs) are cell surface receptors important
for nervous system development, function, and repair (1–3). Vertebrate family members
[RPTPs, leukocyte common antigen-related (LAR) protein, and RPTPδ] and invertebrate
orthologs [e.g., Drosophila LAR (DLAR)] localize to axonal growth cones, regulating
neuronal growth and guidance and participating in excitatory synapse formation and
maintenance (1, 4–8). RPTPσ–/– mice exhibit neurological and neuroendocrine defects (9,
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10), as well as increased nerve regeneration (11–15); RPTPδ-deficient mice show impaired
learning and memory (16). RPTPσ and δ double-mutant mice have a developmental loss of
motor neurons leading to paralysis (17).
Type IIa RPTP extracellular regions interact with heparan sulfate proteoglycans (HSPGs)
and chondroitin sulfate proteoglycans (CSPGs) (5, 7, 12, 18). These proteoglycans modulate
neuronal growth, guidance, and connectivity, typically with CSPGs inhibiting and HSPGs
promoting axon extension (19–23). Up-regulation of CSPGs in glial scar tissue after neural
injury is an important factor limiting central nervous system axon sprouting and
regeneration (2, 21, 24, 25). In adult mouse dorsal root ganglion (DRG) sensory axons, this
CSPG inhibitory effect is mediated, at least in part, by RPTPσ (12). In contrast, in
developing chick retinal ganglion cell axons, RPTPs promotes growth in response to basal
lamina, which contains HSPG ligands (18, 26). We sought to resolve the apparent
conundrum of CSPG-RPTPσ and HSPG-RPTPσ interactions eliciting opposing effects on
neuronal outgrowth with analyses at the cellular and molecular level.
Previous results led to alternative predictions for the potential effects, if any, of HSPGs
acting via RPTPσ in DRG neurons: these might inhibit outgrowth, like CSPGs, or promote
outgrowth, as observed in retinal ganglion cells. Neurocan, a CSPG, reduced outgrowth of
wild-type (WT) DRG neurons by ~60%, as described previously (12), and this inhibitory
effect was decreased in RPTPσ–/– neurons (P < 0.001) (Fig. 1, A to D and G). In contrast,
glypican-2, an HSPG, strongly promoted outgrowth of WT neurons. This promoting effect
was reduced to undetectable levels in RPTPσ–/– neurons, showing a requirement for RPTPσ
(P < 0.01) (Fig. 1, E to G). Heparitinase III treatment of the glypican-2 significantly reduced
its growth-promoting ability (P < 0.005) (fig. S1), indicating that its glycosaminoglycan
(GAG) chains are involved. Chondroitinase ABC and heparitinase III reduced RPTPσ
binding by neurocan and glypican-2 respectively, confirming the specific presence of
heparan sulfate (HS) and chondroitin sulfate (CS) on these proteoglycans and the role of
GAG chains in mediating interactions with RPTPσ (Fig. 1H).
The observed dichotomy in CSPG/HSPG function, apparently mediated through a common
receptor, RPTPσ, is intriguing given that mutagenesis studies indicate a common binding
site for the two proteoglycan classes (12, 18). To investigate the structural basis of
proteoglycan recognition in RPTPσ and type IIa RPTPs in general, we undertook
crystallographic studies. The type IIa RPTP ectodomain is predicted to consist of three I-set
immunoglobulin (Ig)–like domains followed by either five or nine fibronectin (FN) type III
repeats (Fig. 2A). We produced a series of RPTPσ, RPTPδ, and LAR deletion constructs for
structural and functional assays (27), all including the N-terminal Ig domain harboring the
putative GAG binding site (Fig. 2A) (12, 18). We determined crystal structures of the two
N-terminal Ig domains (Ig1-2), which formed the minimal stable unit, for examples across
family members and species (chicken and human RPTPσ, human RPTPδ and LAR,
Drosophila DLAR) [see (28), fig. S2 and tables S1 and S2]. A V-shape arrangement of Ig1
and Ig2 is stabilized by conserved interactions, irrespective of the crystallization conditions
and packing (Fig. 2B and figs. S3 to S5).
RPTPσ residues previously shown to mediate GAG binding (K67, K68, K70, K71, R96, and
R99) (29) lie on loops between Ig1 β strands C-D and E-F, forming an extended positively
charged surface (Fig. 2, B and C). Our crystal structures, supplemented by sequence
comparisons, show that this site is highly conserved across family members and species
(Fig. 2C and fig. S2), suggesting a common GAG binding mode. A 2.05 Å resolution crystal
structure of human LAR Ig1-2 in complex with sucrose octasulfate (SOS), a synthetic
heparin-mimic, confirmed the GAG binding site location and revealed a conformational
plasticity of the C-D (“Lys”) loop (residues K67-F77) (Fig. 2D, figs. S6 to S8, and table S2).
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SOS binding triggered an outwards movement of residues V72 to F77, following rupture of
the R76-D100 salt bridge. K67, K68, and R76 form electrostatic interactions with SOS,
whereas R99 interacts with D100, resulting in a modified topology of the GAG binding
surface but maintaining the overall positive charge (Fig. 2, E and F). Thus, the combination
of basic side chains deployed by the type IIa RPTP GAG-binding site may vary to match the
sulfate chemistry of a particular disaccharide unit, conferring the ability to accommodate
chemically diverse GAGs.
Interaction affinities of RPTPσ sEcto with neurocan and glypican-2, in solid phase binding
assays, were in the same range [10 to 20 nM dissociation constant (Kd)] (Fig. 3, F and G),
similar to those determined in previous studies of CSPGs or HSPGs binding to type IIa
RPTPs (7, 12), although weaker than measured previously for heparin conjugated to bovine
serum albumin (0.3 nM) (18). The glycan binding surface on Ig1 forms an elliptical area of
~35 by 24 Å (Fig. 3A). Comparisons with a compact heparin structure, a helix with a four-
saccharide pitch of 17.5 Å (30), suggested that GAG chains could assemble RPTPσ
oligomers. We therefore incubated a series of size-defined heparin fragments with a RPTPσ
construct containing the six N-terminal domains (Ig1-FN3) (Fig. 2A). Heparin fragments
containing four [degree of polymerization 4 (dp4)] or six (dp6) saccharide residues did not
alter the Ig1-FN3 oligomeric state, as assessed by size-exclusion chromatography coupled
with multi-angle light scattering (MALS) (Fig. 3D and table S3). However, fragments
containing eight (dp8) or ten (dp10) saccharides induced a shift toward a dimeric Ig1-FN3
species (Fig. 3D and table S3). This trend continued as heparin fragments of increasing
length were tested; Ig1-FN3 mixed with dp20 and dp30 formed tri- and tetrameric clusters,
respectively (Fig. 3E and table S3). A quadruple K67, K68, K70, K71 mutation to alanine,
previously shown to impair binding to both CSPGs and HSPGs (12, 18), abolished the
heparin-induced clustering effects (Fig. 3F and table S3). The clustering behavior was
reproduced in MALS measurements for an RPTPσ domain deletion series (Fig. 2A and fig.
S9) and validated for Ig1-2 by analytical ultracentrifugation and native mass spectrometry
(fig. S10). These data provide compelling evidence that the Ig1 GAG-binding site is
necessary and sufficient for receptor clustering dependent on heparin fragment length (figs.
S9 and S10 and table S3). We demonstrated similar heparin-induced oligomerization
characteristics for other type IIa RPTPσ, albeit with some variation (figs. S11 and S12 and
table S3).
We then used MALS to compare the ability of CS and HS GAGs to induce oligomerization.
HS (30 to 150 saccharide units) induced tetrameric clustering of RPTPσ Ig1-FN3, analogous
to dp30 heparin fragments (Fig. 3G and table S3). In marked contrast to heparin or HS,
comparable CS (30 to 150 saccharide units) quantities did not induce clustering of any type
IIa RPTP construct (Fig. 3E and fig. S12). Using fivefold higher CS concentrations, we were
able to detect evidence of binding to RPTPσ Ig1-FN3, but the molecular mass did not shift
to the levels seen for stable GAG-induced oligomers (Fig. 3G and table S3). Because CSPGs
and HSPGs had shown comparable binding affinities to RPTPσ in our solid state assay, we
tested whether CS could compete with HS in the MALS assay. Excess CS inhibited both
HS- and heparin dp10–induced clustering (fig. S12 and table S3). Thus, differences in GAG
chemical structure must be responsible for the contrasting effects of HS and CS on RPTPσ
oligomerization (Fig. 3H).
The competing effects of CS and HS on RPTPσ oligomerization suggest that axon
outgrowth may be determined by relative amounts, rather than independent effects, of HSPG
and CSPG acting on RPTPσ. To investigate this model, we assessed DRG neuron cultures
for expression of endogenous HS and CS. Immunofluorescence showed that both CS and
HS are endogenously produced by these cultures. CS labeling was seen primarily over the
extracellular matrix (ECM), where it was highest adjacent to non-neuronal cells, suggesting
Coles et al. Page 3
Science. Author manuscript; available in PMC 2012 April 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
production of CSPG by these cells, whereas cell bodies and GAP43-labeled neurites showed
little or no evidence of CS labeling and were typically aligned with dark areas in the
immunofluorescence (Fig. 4, A to F, and fig. S14). HS labeling, in contrast, was highest
over cell bodies and neurites, where RPTPσ labeling was also seen (Fig. 4, G to O, and fig.
S14). At higher magnification, RPTPσ labeling revealed a punctate distribution over the
growth cone, as described previously (15), and was similar (although not identical) to the
HS pattern (Fig. 4, P to S). Thus, these results support a model in which endogeneous
HSPGs in these cultures act predominantly in cis on the cell surface, whereas CSPGs are
presented in trans by the ECM (Fig. 4T). Exogenous HSPG or CSPG addition (Fig. 1) would
shift the HSPG:CSPG ratio. Consistent with this interpretation and with the ability of CS to
compete with HS-mediated RPTPσ oligomerization (fig. S12), the addition of CSPG to
DRG cultures could block the outgrowth-promoting effect of exogenous HSPG (P < 0.001)
(fig. S15).
Mechanistic parallels can be drawn for proteoglycan-specific regulation of other cell surface
receptor systems. HS is known to play an essential role in fibroblast growth factor (FGF)
signaling (31), and the number of FGF–FGF receptor protomers in a supramolecular
assembly directly correlates with the size of the GAG chain (32). Opposing HSPG and
CSPG effects have been reported in semaphorin-mediated axon guidance (22). HSPGs and
CSPGs differ in the chemical composition of their GAG chains. The distribution of sulfate
groups (typically one to two per disaccharide) along CS chains is relatively uniform,
whereas HS has a distinct modular composition, with high-sulfation regions (three groups
per disaccharide) flanked by intermediately modified transition zones and variably spaced
by largely unmodified sections almost devoid of sulfation (33). Our observations suggest a
model in which islands of high sulfation present in HS, but not CS, may promote close
packing of RPTPσ molecules.
RPTPσ clustering would translate into an uneven distribution of phosphatase activity on the
cell surface, consistent with localization-based models for receptor action (34). Small
regions depleted in phosphatase activity could enhance the extent and duration of a
phosphorylated state for proteins stimulating neuronal extension (1, 35, 36). Our solution
and cellular data are consistent with a model in which increasing the CSPG:HSPG ratio
shifts the balance away from growth-promoting RPTPσ clusters, stalling neuronal growth
cones (Fig. 4T). This model predicts that molecules able to promote RPTPσ oligomerization
may prove beneficial in strategies to facilitate plasticity and regeneration after nervous
system injury. More generally, proteoglycan-binding is a common property of many cell
surface signaling systems involved in normal biology and disease. Our results point to a
mechanism by which differences in the structure of GAG chains can serve as a stop/go
molecular switch for cell motility and may provide a general paradigm in the biology of cell
surface signaling.
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Fig. 1.
RPTPσ-GAG interactions modulate contrasting growth responses. (A, C, E) WT and (B, D,
F) RPTPσ–/– P8 mouse DRG neurons grown on poly-D-lysine/laminin alone (control) or
supplemented with either neurocan or glypican-2, imaged by GAP-43 immunolabeling.
Scale bar in (A), 100 μm. (G) Total neurite outgrowth quantitation reveals neurocan
inhibition and glypican-2 promotion. Both effects are reduced in RPTPσ–/– neurons. (H)
Pretreatment with chondroitinase ABC (ChABC) or heparitinase III (HPNIII) reduced
binding of neurocan and glypican-2, respectively, to RPTPσ in solid-phase binding assays. n
= 3 to 4 mice for each genotype. **P < 0.001; *P < 0.01; Student's t test. Error bars indicate
SEM. AP, alkaline phosphatase tag; Fc, immunoglobulin fragment crystallizable tag.
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Fig. 2.
Structure of the proteoglycan binding site. (A) Type IIa RPTP domain organization. N,
amino-terminus (extracellular); SP, secretion signal peptide; TM, transmembrane; C, C
terminus (intracellular); Ig, immunoglobulin-like; FN3, fibronectin type-III. The ectodomain
may be remodeled by alternative splicing (1). Numbering corresponds to chicken RPTPσ.
(B) Ribbon diagram of chicken RPTPσ Ig1-2. Blue sticks represent residues important for
proteoglycan binding (12, 18). (C) Solvent-accessible surfaces of Ig1-2 crystal structures,
colored by electrostatic potential (±5kT/e, where k is the Boltzmann constant, T is
temperature, and e is the charge on an electron). Red, acidic; blue, basic. (D) SOS induces
movement of the proteoglycan binding Lys-loop in human LAR (green) relative to the apo-
protein (beige). Surface representations of the boxed region in (C) for apo-LAR (E) and
SOS-bound LAR (F) highlight the malleability of the proteoglycan binding surface.
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Fig. 3.
GAG-induced oligomerization of RPTPσ. (A) Dimensions of the proteoglycan binding
surface from chicken RPTPσ Ig1-2 crystal structure. (B) and (C) Neurocan-alkaline
phosphatase (NC-AP) and glypican-2-AP (Glyp2-AP) bind to immobilized mouse RPTPσ
sEcto-Fc with comparable affinities. Kd values were ~21 nM for RPTPσ-neurocan and ~10
nM for RPTPσ–glypican-2 interactions, assuming one-to-one binding. mOD, optical density
units × 10–3. (D to G) Size-exclusion chromatography coupled to MALS was used to
investigate the oligomerization state of human RPTPσ Ig1-FN3 in solution with an excess of
varying-length GAGs. Protein was incubated alone (red), with dp4 (orange), dp6 (purple),
dp8 (green), dp10 (blue), dp20 (light green), or dp30 (gray). Heparin dp8 was the minimum
length of heparin oligosaccharide to promote oligomerization (D); longer heparin
oligosaccharides resulted in larger RPTP oligomers (E). The oligomerization state of a
quadruple K67A/ K68A/K70A/K71A mutant of RPTPσ (Ig1-FN3 ΔK) was insensitive to
heparin addition (F). HS but not CS induced oligomerization of RPTPσ Ig1-FN3; “×5”
indicates increased GAG amounts (G) (28). Refractive index traces (scaled within each
panel) and measured molecular weights are represented by bold and dashed lines,
respectively. Refractive index peaks indicated by an asterisk correspond to excess glycan
ligand. AU, arbitrary units; kDa, kilodaltons. (H) Model for RPTPσ Ig1-2 clustering along
the highly sulfated domains of HS based on an unperturbed helical heparin structure (Protein
Data Bank accession code 1HPN).
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Fig. 4.
Immunolocalization of endogenous HS, CS, and RPTPσ in DRG neuron cultures. (A to F)
Immunolocalization of CS (red) with GAP43 neuronal marker (green) and 4′,6-diamidino-2-
phenylindole (DAPI) nuclear stain (blue). Colors are merged in (E) and (F). Boxed areas in
(A) and (E) are enlarged in (B) and (F), respectively. Open arrowheads denote dark areas of
low CS labeling that overlap with cell bodies and axons. GAP43 labeled axon in (F) grows
over a non-neuronal cell at lower left. (G to L) HS (red) with GAP43 (green) and DAPI
(blue). Colors are merged in (K) and (L). Boxed areas in (G) and (K) are enlarged in (H) and
(L), respectively. Solid arrowheads indicate HS labeling over GAP43-labeled neuronal
processes. (M to S) Immunolocalization of HS (red) with RPTPσ (green). (M to O) Labeling
of a neuron, including cell body and neurites (arrowheads). (P to S) A growth cone
(arrowhead) with axon shaft (arrow) at higher magnification. (S) Differential interference
contrast image. Both HS and RPTPσ show punctate labeling, in similar although not
identical patterns. Scale bar, 60 μm [(A), (C) to (E), (G), (I) to (K), and (M) to (O)] and 6
μm [(P) to (S)]. (T) Model for type IIa RPTP-proteoglycan interactions and their distinct
functional consequences. Islands of high/intermediate sulfation on HS chains (shown in
pink/yellow) stabilize receptor oligomers, causing an uneven distribution of tyrosine
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phosphatase activity and formation of microdomains with high phosphotyrosine levels and
supporting neuronal extension. Conversely, secreted CS (blue chains), present in glial scar
tissue, is unable to induce tight RPTPσ oligomerization, competing with HS and inhibiting
axon growth. Regulatory mechanisms might include shedding (1); crystal structure of
human RPTPσ Ig1-3 reveals an exposed furinlike protease cleavage site in the Ig2-3 linker
(scissors) (fig. S13).
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